• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血因子 XIII 天然存在的 R260C 突变 A 亚基二聚体组装受损和稳定性降低。

Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.

机构信息

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, 990-9585 Japan.

出版信息

J Biochem. 2012 Nov;152(5):471-8. doi: 10.1093/jb/mvs088. Epub 2012 Aug 25.

DOI:10.1093/jb/mvs088
PMID:22923741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3619964/
Abstract

Factor XIII (FXIII) consists of catalytic A subunits (FXIII-A) and carrier B subunits. Congenital FXIII deficiency is a severe bleeding disorder. We previously identified an R260C missense mutation and an exon-IV deletion in Japanese patients' F13A genes. To characterize the molecular basis of this disease, we expressed a wild-type and the mutant FXIII-A in yeast cells for detailed investigation, by taking advantage of yeast's ability for mass protein production. The mutant proteins were expressed less efficiently than the wild-type and considerably aggregated; even their non-aggregated forms became aggregated with time. Ultra-centrifugation and gel-filtration analyses revealed that the mutants were of extremely high-molecular weight, and that the wild-type formed a dimer. Notably, a part of the R260C mutant was found in monomer form. This was consistent with the prediction by molecular modelling that the mutant molecule would lose the electrostatic interaction between the two monomers, leading to their inability to form a dimer. The mutants lost enzymatic activity. The mutants were only partially converted by thrombin to the cleaved form. The wild-type was fully converted and activated. These mutants might have significantly altered conformations, resulting in their aggregation in vitro, and may ultimately lead to FXIII deficiency in vivo as well.

摘要

凝血因子 XIII(FXIII)由催化 A 亚基(FXIII-A)和载体 B 亚基组成。先天性 FXIII 缺乏症是一种严重的出血性疾病。我们之前在日本患者的 F13A 基因中发现了 R260C 错义突变和外显子-IV 缺失。为了阐明该疾病的分子基础,我们利用酵母大量生产蛋白质的能力,在酵母细胞中表达了野生型和突变型 FXIII-A,进行了详细研究。与野生型相比,突变型蛋白的表达效率较低,且大量聚集;即使是非聚集形式也会随着时间的推移而聚集。超速离心和凝胶过滤分析表明,突变体具有极高的分子量,而野生型形成二聚体。值得注意的是,R260C 突变体的一部分以单体形式存在。这与分子建模的预测一致,即突变分子将失去两个单体之间的静电相互作用,导致它们无法形成二聚体。突变体失去了酶活性。突变体仅部分被凝血酶转化为裂解形式,而野生型则完全转化并激活。这些突变体可能具有显著改变的构象,导致其在体外聚集,并可能最终导致体内 FXIII 缺乏。

相似文献

1
Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.凝血因子 XIII 天然存在的 R260C 突变 A 亚基二聚体组装受损和稳定性降低。
J Biochem. 2012 Nov;152(5):471-8. doi: 10.1093/jb/mvs088. Epub 2012 Aug 25.
2
Proteosomal degradation of naturally recurring R260C missense and exon-IV deletion mutants of factor XIII A-subunit expressed in mammalian cells.在哺乳动物细胞中表达的因子 XIII A 亚单位的天然存在的 R260C 错义突变和外显子-IV 缺失突变体的蛋白酶体降解。
Haemophilia. 2013 May;19(3):415-9. doi: 10.1111/hae.12072. Epub 2012 Dec 20.
3
Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit.凝血因子 XIII:先天性凝血因子 XIII 缺乏症,获得性凝血因子 XIII 缺乏症,凝血因子 XIII A 亚单位,和凝血因子 XIII B 亚单位。
Arch Pathol Lab Med. 2014 Feb;138(2):278-81. doi: 10.5858/arpa.2012-0639-RS.
4
Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations.巴基斯坦的先天性因子 XIII 缺乏症:七个家族的特征分析及四个新突变的鉴定
Haemophilia. 2014 Jul;20(4):568-74. doi: 10.1111/hae.12340. Epub 2013 Dec 16.
5
Effect of four missense mutations in the factor XIII A-subunit gene on protein stability: studies with recombinant proteins.凝血因子 XIII A 亚基基因中四个错义突变对蛋白质稳定性的影响:重组蛋白研究
Blood Coagul Fibrinolysis. 2006 Mar;17(2):125-30. doi: 10.1097/01.mbc.0000214707.65750.f4.
6
Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines.严重先天性因子 XIII 缺乏症由 F13A 基因中的新型 W187X 和 G273V 突变引起;根据 ISTH/SSC 指南进行诊断和分类。
Haemophilia. 2014 Mar;20(2):255-62. doi: 10.1111/hae.12298. Epub 2013 Nov 29.
7
Molecular modeling predicts structural changes in the A subunit of factor XIII caused by two novel mutations identified in a neonate with severe congenital factor XIII deficiency.分子建模预测了因子 XIII A 亚基的结构变化,这是在一名患有严重先天性因子 XIII 缺乏症的新生儿中发现的两种新突变引起的。
Thromb Res. 2012 Sep;130(3):506-10. doi: 10.1016/j.thromres.2012.05.003. Epub 2012 May 25.
8
Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.因子 XIII 拓扑结构:用单分子原子力显微镜研究 B 亚基的组织和激活时的变化。
J Thromb Haemost. 2019 May;17(5):737-748. doi: 10.1111/jth.14412. Epub 2019 Mar 14.
9
Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of the A-subunit.凝血因子 XIII 缺乏症中的四种新突变:对 A 亚基表达和结构的影响
Blood. 1996 Jan 1;87(1):141-51.
10
Factor XIII deficiency: an update.因子 XIII 缺乏症:更新。
Semin Thromb Hemost. 2013 Sep;39(6):632-41. doi: 10.1055/s-0033-1353392. Epub 2013 Aug 8.

引用本文的文献

1
Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration.凝血因子 XIII-A 和 -B 亚基的相互稳定是血浆 FXIII 浓度的决定因素。
Blood. 2024 Feb 1;143(5):444-455. doi: 10.1182/blood.2023022042.
2
Activation of factor XIII is accompanied by a change in oligomerization state.因子 XIII 的激活伴随着寡聚化状态的改变。
FEBS J. 2017 Nov;284(22):3849-3861. doi: 10.1111/febs.14272. Epub 2017 Oct 3.
3
Impaired Activity of Blood Coagulant Factor XIII in Patients with Necrotizing Enterocolitis.
Sci Rep. 2015 Aug 17;5:13119. doi: 10.1038/srep13119.

本文引用的文献

1
Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.重组凝血因子 XIII:先天性凝血因子 XIII 缺乏症的安全新型治疗方法。
Blood. 2012 May 31;119(22):5111-7. doi: 10.1182/blood-2011-10-386045. Epub 2012 Mar 26.
2
Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency.
Haemophilia. 2012 Jan;18(1):e6-8. doi: 10.1111/j.1365-2516.2011.02622.x. Epub 2011 Aug 4.
3
Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function.鉴定八个新型凝血因子 XIII 亚基 A 突变:对结构和功能的影响。
Haematologica. 2010 Jun;95(6):956-62. doi: 10.3324/haematol.2009.017210. Epub 2010 Feb 23.
4
Sushi domains in the B subunit of factor XIII responsible for oligomer assembly.凝血因子 XIII B 亚基中负责寡聚体组装的寿司结构域。
Biochemistry. 2008 Aug 19;47(33):8656-64. doi: 10.1021/bi8006143. Epub 2008 Jul 25.
5
Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.给因子XIII B亚基基因敲除小鼠注射因子XIII B亚基可提高血浆因子XIII A亚基水平。
Int J Hematol. 2008 Jan;87(1):60-8. doi: 10.1007/s12185-007-0005-z. Epub 2007 Dec 5.
6
Phenotype-genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations.8例波兰遗传性凝血因子XIII缺乏症患者的表型-基因型相关性:鉴定出三种新突变
Haemophilia. 2007 Sep;13(5):649-57. doi: 10.1111/j.1365-2516.2007.01517.x.
7
International registry on factor XIII deficiency: a basis formed mostly on European data.国际凝血因子 XIII 缺乏症注册研究:主要基于欧洲数据形成的一个数据库。
Thromb Haemost. 2007 Jun;97(6):914-21.
8
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.重组因子XIII - A2用于先天性因子XIII缺乏症患者的安全性和药代动力学
Blood. 2006 Jul 1;108(1):57-62. doi: 10.1182/blood-2005-02-0788. Epub 2006 Mar 23.
9
Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder.六种导致先天性因子 XIII 缺乏的新型 A 亚基突变的特征分析及首例诊断为此罕见出血性疾病患者的分子分析
Thromb Haemost. 2006 Jan;95(1):77-84.
10
Effect of four missense mutations in the factor XIII A-subunit gene on protein stability: studies with recombinant proteins.凝血因子 XIII A 亚基基因中四个错义突变对蛋白质稳定性的影响:重组蛋白研究
Blood Coagul Fibrinolysis. 2006 Mar;17(2):125-30. doi: 10.1097/01.mbc.0000214707.65750.f4.